Technological order and technology transfer of the vaccine for COVID-19 in Brazil: a case study of the model used by AstraZeneca/Oxford and Fiocruz
DOI:
https://doi.org/10.22239/2317-269x.02068Keywords:
Technological Order, COVID-19 Vaccine, ETEC, Public Technology Procurement, Demand-side Innovation PolicyAbstract
Introduction: The COVID-19 pandemic, caused by SARS-CoV-2, showed a rapid increase in the number of cases and deaths in the five continents, with a major impact in the public health and the economy of the countries. The effects of COVID-19 have highlighted an increase in existing inequalities in society. A global mobilization for the development and rapid production of vaccines was needed to meet the emergency demand caused by COVID-19. Objective: To discuss actions carried out by Fiocruz in the challenges imposed by the emergency to combat the disease, in addition to analyzing and discussing the partnership established between Bio-Manguinhos/Fiocruz and AstraZeneca, through Technological Order (ETEC), aiming at the verticalized Technology Transfer (TT) of the CHADOX1 NCOV-19 vaccine. Method: A documentary analysis of a descriptive nature and qualitative approach was carried out, based on the search for scientific articles on the subject, and institutional documents, as well as a thorough procedural analysis of ETEC, formalized between Fiocruz and AstraZeneca. Results: Although the National Policy for Technological Innovation in Health (PNITS) describes three viable legal instruments for formalizing partnerships, ETEC was the most adequate to meet the demands imposed by the health emergency of COVID-19, reinforcing the importance of using the State’s purchasing power as an instrument for strengthening the State Health Care System (SUS) within the scope of the Health Industrial Complex. Conclusions: Even considering the health emergency caused by COVID-19, Bio- Manguinhos/Fiocruz managed to establish a partnership with AstraZeneca, aiming at the TT for the national verticalized production of the COVID-19 vaccine, for the attendance of SUS ́s demand. The legal instrument chosen for the formalization of the partnership was ETEC, the first used in the public health area, which proved feasible to be reproduced in future partnerships aiming at the internalization of technologies of national interest. From the absorption of this technology, Bio-Manguinhos will be able to develop new vaccines of HM’s interest using the same technology.
Downloads
Author Biographies
-
Silvania lacovino Dantas, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil
-
Luciene Ferreira Gaspar Amaral, Secretaria de Ciência, Tecnologia e Insumos Estratégicos (SCTIE), Ministério da Saúde, Brasília, DF, Brasil
-
Jorge Carlos Santos da Costa , Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Silvania lacovino Dantas, Luciene Ferreira Gaspar Amaral, Jorge Carlos Santos da Costa (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
COPYRIGHT ALLOWANCE The author (s) hereinafter designated as the ASSIGNOR hereby assign and transfer, free of charge, the ownership of the copyrights related to this ARTICLE to the Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debate, represented by FUNDAÇÃO OSWALDO CRUZ, established at Av. Brasil, nº 4365, Manguinhos, Rio de Janeiro, RJ, Brazil, CEP 21045-900, under the conditions set out below: (a) The terms and conditions set forth in this Agreement shall apply to the following: 1. The ASSIGNOR declares that they s(he) is (are) the author (s) and owner (s) of the copyrighted property of the ARTICLE submitted. 2. The ASSIGNOR declares that the ARTICLE does not infringe the copyrights and / or other property rights of third parties, that the disclosure of images (if any) has been authorized and that they s(he) assume(s) full moral and / or property liability for its content, before third parties. 3. THE ASSIGNOR assigns and transfers all copyrights relating to the ARTICLE to the ASSIGNEE, especially the rights of editing, publication, translation into another language and reproduction by any process or technique. The ASSIGNEE becomes the exclusive owner of the rights related to the ARTICLE, and any reproduction, totally or partially, is prohibited in any other means of publicity, printed or electronic, without prior written authorization from the ASSIGNEE. 4. The assignment is free and, therefore, there will be no remuneration for the use of the ARTICLE by the ASSIGNEE.
